BIO vs NVCT · rev $651.0M vs $304.5M cap
BIO (BIO) versus Nuvectis Pharma Inc (NVCT) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
Nuvectis Pharma Inc (NVCT) is a biotechnology company listed on NASDAQ.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
NVCT does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. NVCT currently screens at market cap $304.5M.
Not investment advice. Open the BIO and NVCT stock pages for the full models.
Not investment advice.